“Cellular agriculture”: current gaps between facts and claims regarding “cell-based meat”
Animal Frontiers · 15.04.2023 · 13 (2) · 68-74
DOI: 10.1093/af/vfac092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Frontiers, online erschienen am 15.04.2023. Verfasst von Paul Wood und 4 weiteren Autor:innen. Beteiligte Einrichtung: Monash University, Clayton, Victoria 3800, Australia. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There has been a significant increase in the number of scientific articles related to “cell-based meat” (‘CBM’), which is in line with the current interest from the scientific community and consumers, but mainly from investors, food industry, and regulatory bodies. Despite the billions of dollars being invested in “cellular agriculture”, there are significant technical, ethical, regulatory, and commercial challenges to getting these products widely available in the market. In addition, the widespread adoption of such technologies can exacerbate global inequity between affluent and poor individuals and between high- and low-income countries. Current ‘CBM’ products are not identical to the products they aim to replace. First, there is still considerable dissimilarity at the level of sensory, nutritional, and textural properties, while important quality-generating steps in the conversion of muscle into conventional meat are missing. Second, many societal roles of animal production beyond nutrition can be lost, including ecosystem services, co-product benefits, and contributions to livelihoods and cultural meaning. Detailed production procedures are not available, making it impossible to corroborate the many claims related to their product characteristics and sustainability. ‘CBM’ companies arguing that the cost of all technology will eventually be significantly reduced often quote Moore’s law. However, biological systems like ‘CBM’ have natural limits and feedback mechanisms that negate this law. In alignment with an emerging Silicon Valley–style outlook on the future of food, a bold 2019 report by the think tank RethinkX claimed that by 2030 the U.S. meat and dairy industries would be bankrupt due to “cellular agriculture” taking over their traditional markets (Tubb and Seba, 2019). This claim was based on their view of how quickly precision fermentation and “cell-based meat” (‘CBM’) technology would be developed and scaled, so they could compete on price parity with traditional livestock production (Leroy et al., 2023). However, estimates on future evolutions differ wildly. For example, a 2018 report ordered by the Flemish government predicted that the consumption of “clean meat” may start in approximately 2040 (van Diepen et al., 2018). Ten years ago, however, it was already touted that “clean meat” would be available in the market by 2017 (EC, 2012). By now, it is clear that it is difficult to make predictions and that many technical challenges remain before such products can become commercially available. Nevertheless, over the past few years, billions of dollars have been invested in these technologies related to cellular agriculture (including precision fermentation and CBM) and hundreds of new start-ups have been created around the globe (Boukid and Gagaoua, 2022). The terminology for developed products is still under discussion; for recognizability, we will use the term “cell-based meat”, though the term “meat” imparts characteristics that have not been proven, as we will discuss. The reasons for proposing new protein alternatives, including ‘CBM’, are diverse and divergent, but mainly related to ethical concerns about animal welfare and the possible impact of animal protein production on the environment (Siddiqui et al., 2022). This paper briefly describes the technical, regulatory, and consumer challenges facing both precision fermentation and CBM and examines their potential to disrupt the meat and dairy industries, with a focus on ‘CBM’ as an alternative to farm animal proteins. Precision fermentation is the process of engineering the gene sequence for a specific protein into a bacterium or yeast strain and then growing that strain in large-scale fermenters, to produce the required protein. This technology has been used for decades in the biotechnology sector. It was previously referred to as “recombinant protein production” and is used for many vaccines and drugs, such as insulin (Wood and Tavan, 2022). In the food sector, precision fermentation has been used for decades to produce enzymes for cheese making or conventional fermentation. Chymosin, used in cheese manufacturing for milk coagulation, was originally extracted from the stomachs of calves before manufacturers switched to a recombinant form of this enzyme (expressed in a range of organisms). Recently, companies have used this technology to produce key proteins for the food industry. Impossible Foods uses a precision-fermentation form of hemoglobin to give their plant-based burgers the look and smell of red meat when they are cooked. As another example, The Every Company is producing chicken-free egg products using precision fermentation technology. Until now, the major focus has been on dairy products. Around 60% of the companies in the precision fermentation space are focusing on the production of key dairy proteins. Perfect Day was the first company to release a commercial dairy product containing β-lactoglobulin. Other companies are now following their lead. One of the goals for companies like All G Foods and Eden Brew is to recreate a liquid milk, which contains both the whey and casein proteins that are needed to form a micelle, to give this product the full functionality of cow’s milk. These products will still need to have added fats, sugars, minerals, and vitamins to approach the nutritional content of cow’s milk. There has been significant investment in the precision fermentation space and many predictions that this technology is going to disrupt the traditional meat and dairy industries; however, there are many technical, regulatory, and consumer challenges that need to be addressed. The major technical challenge will be the cost of goods, with precision fermentation being significantly more expensive. For milk proteins, a range of yeast strains can produce recombinant proteins at a rate of 10–30 g/l, but these proteins then need to be separated from the yeast cells and cell debris using a variety of downstream processing techniques that can account for up to 60% of the cost of manufacture. Precision fermentation technology will also be critical for the ‘CBM’ sector to produce the various growth factors and perhaps other compounds required to culture mammalian cells. To scale-up precision fermentation, companies use fermenters at >100,000-l capacity, which will require complex engineering and energy intensive processors. In the USA, the regulatory process is relatively straightforward with the ability to use the ‘Generally Recognized As Safe’ classification. In Europe, however, it will be difficult to register precision fermentation products under the current legislative constellation, as they use genetically modified organisms in the manufacturing process. Finally, the labeling of precision fermentation products will vary considerably in different regions, and this has the potential to confuse consumers who are cautious of genetically modified products. Based on these issues, precision fermentation will be unlikely to disrupt the livestock industry but may provide high-value products for niche markets. Companies aspire to produce meat without using animals (Figure 1). It is touted that such ‘CBM’ will be the same as meat from farm animal(s). Meat from animals is typically derived from the skeletal muscle of slaughtered animals, though other tissues such as liver and products of the fifth quarter are also consumed, of which the amounts depend on the region in the world and local food cultures. Here, we will focus on meat derived from skeletal muscle. Currently, many hurdles remain to make ‘CBM’ despite several decades of work stemming mainly from the fields of regenerative medicine and monoclonal antibody production. These hurdles have been summarized in Thorrez and Vandenburgh (2019) and still remain. The envisioned production procedures tend to oversimplify the complexity and growth of skeletal muscle. Skeletal muscle is a tissue which is composed of several cell types, the most abundant one being myofibers. Other cell types include connective tissue cells (fibroblasts), fat cells (adipocytes), endothelial cells, and blood cells. The current focus is mainly on the expansion of myoblasts, the precursor cells to myofibers. However, it is still unclear how long cells from biopsies can be expanded, as these primary cells undergo senescence during long-term expansion. Other precursor cell types (e.g., pluripotent cells) are being explored, but the creation of these cells, as well as the efficient differentiation towards myoblasts, currently involves genetic engineering. Simplified schematic representation of how ‘cell-based meat’ is touted to be produced using ‘cellular agriculture’ without rearing animals. Sometimes, the expansion phase is compared to fermentation. However, there is a stark difference between growth rates of bacteria and yeast vs. animal cells. Yeast can expand well over 1000× in less than a day, whereas this takes over 10 days for animal cells. Adding other cell types, in a way that spatially is similar to muscle, involves a co-culture setup, which adds to the complexity. Myoblasts need to fuse to form multi-nucleated myotubes and these myotubes are an intermediate towards myofibers, which occurs in animals during prenatal development. These myotubes are aligned (driven by unidirectional forces between attachments to the bones) and to create a similar alignment for ‘CBM’, manufacturing techniques and edible scaffold materials need to be developed. After birth, the myofibers then grow in volume and contractile strength since the organism is actively using them. The properties of muscle from fetuses and newborns (which seldomly is consumed) are vastly different from the muscle of adult animals. Building up proteins from the contractile apparatus, which are characteristics for skeletal muscle, requires the prolonged stimulation of muscle. Such stimulation is not currently accounted for and will require bioreactor development which will significantly increase the envisioned production time. As there is no product nor protocol available, most of the claims related to the production of ‘CBM’ in view of sustainability improvements (e.g., energy or water use) seem not scientifically substantiated or remain at best speculative, especially for its environmental footprint (Lynch and Pierrehumbert, 2019; Rodríguez Escobar et al., 2021). The ‘CBM’ products are not commercialized because the current industrial production is still not economically viable due to the high production costs as well as lack of regulatory framework. In fact, one of the greatest challenges facing the scaling of ‘CBM’ manufacturing is the cost of goods for these products. This is driven primarily by the cost of the culture media, the need for high quality facilities, and the capital cost for sophisticated manufacturing facilities. The biotechnology industry has been using cell-based systems for the manufacture of monoclonal antibody therapeutics for several decades and this is an expensive technology. The use of serum-free media is standard but more expensive than the use of serum, due to the cost of the recombinant growth factors. With ‘CBM’, the final product of cell culture will be the cells themselves, which can be used as a cell slurry or induced to undergo muscle fibers differentiation. Once this step has occurred, the cells will be exceedingly difficult to handle, and this part of the manufacturing process is yet to be fully described. Many ‘CBM’ companies are claiming that the costs will be dramatically reduced using large-scale bioreactors at up to a 250,000-l scale. However, the only product registered so far is produced at a 5-l scale, so validating these systems at scale will be a major challenge. In addition, the use of antibiotics will not be permitted, and these larger scale fermentations will require around 90-days continuous sterile culture. Another claim is that ‘CBM’ manufacturing will not require the level of biosecurity used in the biopharma industry, yet most of these quality requirements are driven by the need to maintain sterile systems. The cost of large-scale ‘CBM’ facilities has been estimated at $600M U.S. and the depreciation costs of these facilities will be a major component of the final cost of goods. While interesting, other technology that is being developed for ‘CBM,’ like edible cell-scaffolds and 3D printing with multiple cell types, just add to the challenge of scaling and cost of goods. The development of blended products with plant-based material will help to reduce costs and stabilize formulation. Some companies are focusing on culturing fat cells, with the view that they will only need to add 5% of these cells to their formulations to give the product the hint of meat. Proponents of CBM frequently use the concept of Moore’s Law, the idea that the cost of production for new technologies decreases exponentially over time, to argue that this will also be the case with CBM. However, while Moore’s law has been predictive with the cost of production for physical technologies like computers and high-throughput omics methods, it has never been applied to a biological system due to the complexity of the biological events and mechanisms underpinning cell growth. At present, despite the claims of companies, such products are not ready for the market. To the best of our knowledge, only one lab-based food product is registered (in Singapore) and has been temporarily available in very limited quantities. In addition, production protocols are not available for independent testing by academics or regulatory agencies (Figure 2). Therefore, any claims related to nutritional content cannot be verified as such. Indeed, much remains to be inferred based on available research-scale protocols, as was conceptually analyzed by Fraeye et al. (2020). Sensory properties of meat such as texture, color, and flavor can perhaps be adjusted with food engineering techniques to create products with similar appearance to meat. However, the use of these products in downstream cooking applications may be limited as these characteristics may change during further processing steps such as heating and interaction with other ingredients. It is much harder to make statements related to nutritional characteristics, although these products can be suitable for people having adverse reactions to peas, soy, and gluten. Meat contains highly digestible proteins with essential amino acids, vitamins, and minerals (see elsewhere in this Special Issue). However, while nutrients can be added to meat replacement products, the cost (both in economic and sustainability terms) of this is unknown. Moreover, simply adding components may lead to a different bioavailability, for example, the extent and rate by which they are absorbed by the body. Summary of the remaining challenges and questions related to the future of ‘cell-based meat’ (‘CBM’). As described by Chriki et al. (2022), an important question pertains to the legal nature of ‘CBM’: is it really meat? According to the American Meat Science Association (Boler and Woerner, 2017), the European regulation (Annex I of Regulation No. 853/2004), and other legal definitions (Ong et al., 2020), meat comes from a part (muscles and/or edible tissues) of an animal consumed as food. Therefore, ‘CBM’ does not currently qualify as meat except if we consider living cells as part of an animal (Ong et al., 2020). To be considered meat, ‘CBM’ must be sourced from an animal, proven to be safe for consumption, and be similar in composition, nutritional value, and sensory quality to meat from farmed animals, which is not yet the case (Boler and Woerner, 2017). In addition, to consider ‘CBM’ as a novel food (within EU legislation) means that it should be safe and properly labeled, so as not to mislead consumers. From a biological point of view, meat is the final product of aged muscle through a maturation process (a well-known process by butchers), just as wine originates from grape juice through winemaking. The current cellular agriculture process, however, produces muscle fibers/cells and not meat. Therefore, consumers who are familiar with what meat represents within their culinary and agricultural legacies tend to decline calling it “meat”, unlike vegan activists who see it as a welcome strategy to eliminate meat from the food system and, therefore, wish to give it maximum market potential by capturing the meat category (Gousset et al., 2022). Additionally, various societal roles of animal production beyond nutrition can be lost in the process. This includes the many ecosystem services offered by livestock, the generation of edible and non-edible co-products (e.g., hides, wool, manure, serum, and contributions to and the generation of cultural meaning. Finally, still from a societal it has been that ‘CBM’ may exacerbate global including economic between 2022). The technology being under the of on and high and legal may lead to the creation of and a further expansion of food 2022). in view of market are often (Gousset et al., 2022). This is not as consumers are being about a product which does not yet with the of In addition, most may not what ‘CBM’ is and confuse it with any other of meat (e.g., plant-based to the and to it are also often Indeed, many would like to the product for which does not they would it for Therefore, the of ‘CBM’ is often because it is based on to and not on to ‘CBM’ Many that who a high tend to be and highly at in major but not about ‘CBM’ and are already to reduce meat consumption a variety of reasons including concerns about animal welfare and environmental and less consumers are more and concerns about the future of the livestock and and Such consumers also the and of the product and a In any to is since most in in and in to less for ‘CBM’ compared to conventional meat et al., 2022). All these and may differ from to with being in traditional and being the challenges related to food are the such as in and agriculture”, including ‘CBM’ and precision fermentation, has been as an alternative for producing future food proteins by dairy and meat without animals. The development of such novel despite several ethical is by a of the creation of and media It has into a for societal often with Currently, however, these new food products are not available for consumption in nor are they to independent on economic or scientific Indeed, the of technical challenges related to the and production of ‘CBM’ are not available for and independent in of their nutritional, and or The of and the or poor cultural by consumers, mainly because of lack of and about the are other to societal Therefore, they are well only by a category of people market or animal The other of these products are the limited on the long-term and environmental impact they claim less and related with cellular engineering. regulatory and of of are to product requirements for of these and to such novel while both consumer and environmental Finally, we that the need for more proteins to the growing will to be the of in the production of proteins and meat must in however, that most of the growth in will be in countries. major challenges that need to be further considered in the development of such novel from “cellular agriculture” will be their price and as well as how they are in a and food framework. has from and and was of the In for the and and was an in the of is of the for and an part of the of and the Science and at and a for various (e.g., Thorrez has a in over decades of with animal cell including the development of for gene cell muscle tissue applied systems and current with cell and the engineering of a blood in muscle, for muscle and and towards applications regenerative and meat in and European and with industry, for testing and is a at and of the Association for muscle and consumer was of the and and of the is an of the European of Science and of th
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Monash University, Clayton, Victoria 3800, Australia.
- Tissue Engineering Lab, Department Development and Regeneration, KU Leuven Kulak, Kortrijk, Belgium.
- INRAE, University of Clermont Auvergne, Vetagro Sup, UMR Herbivores, Theix, 63122, Saint-Genès-Champanelle, France.
- PEGASE, INRAE, Institut Agro, 35590 Saint-Gilles, France.
Zitieren
APA
Wood, P., Thorrez, L., Hocquette, J. F., Troy, D., & Gagaoua, M. (2023). “Cellular agriculture”: current gaps between facts and claims regarding “cell-based meat”. Animal Frontiers, 13(2), 68-74. https://doi.org/10.1093/af/vfac092
Vancouver
Wood P, Thorrez L, Hocquette JF, Troy D, Gagaoua M. “Cellular agriculture”: current gaps between facts and claims regarding “cell-based meat”. Animal Frontiers. 2023;13(2):68-74. doi:10.1093/af/vfac092
BibTeX
@article{Wood2023,
author = {Wood, Paul and Thorrez, Lieven and Hocquette, Jean-François and Troy, Declan and Gagaoua, Mohammed},
title = {“Cellular agriculture”: current gaps between facts and claims regarding “cell-based meat”},
journal = {Animal Frontiers},
year = {2023},
volume = {13},
number = {2},
pages = {68--74},
doi = {10.1093/af/vfac092}
}
EUVIMED